Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Renal Research Inc.

Neither a doctor nor a teaching hospital

Research payments

$16,257,908

1,803 payments

Through program year 2025, Total Renal Research Inc. is reported as receiving $16,257,908 in research payments, across 1,803 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$9,837,852	1,082
2024	Research	$3,944,938	490
2023	Research	$2,438,207	216
2022	Research	$36,912	15

Breakdown

Who paid Research payments · program years 2022–2025

CSL Behring $15,310,333 1,495 payments
Alnylam Pharmaceuticals Inc. $947,575 308 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $15,310,333 1,495 payments
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $843,902 249 payments
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels $103,673 59 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.